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SUMMARY
Background
The proportion of patients who respond to proton pump inhibitor (PPI)
therapy is about 20% lower in those with non-erosive reflux disease
(NERD) than in those with erosive oesophagitis.
Aim
To assess efficacy and safety of dexlansoprazole MR, a PPI using Dual
Delayed Release technology, in NERD patients.
Methods
In this 4-week, double-blind, placebo-controlled study, 947 NERD
patients randomly received dexlansoprazole MR 30 mg, 60 mg or placebo
once daily (QD). The percentages of 24-h heartburn-free days (primary)
and nights without heartburn (secondary) were assessed from patients’
daily diaries. Investigators also assessed symptoms. Patients completed
validated quality of life and symptom severity questionnaires.
Results
Dexlansoprazole MR provided significantly greater median percentages
of 24-h heartburn-free days (54.9% and 50.0% for the 30- and 60-mg
doses vs. 17.5% for placebo, P < 0.00001) and nights without heartburn
(80.8% and 76.9% vs. 51.7%, P < 0.00001 vs. placebo). Dexlansoprazole
MR also reduced symptom severity. Quality of life improvements in
patients receiving dexlansoprazole MR were consistent with clinical
efficacy endpoints. Percentages of patients experiencing treatment-
emergent adverse events were similar among groups.
Conclusions
Dexlansoprazole MR 30 and 60 mg were superior to placebo in provid-
ing 24-h heartburn-free days and nights in NERD patients. Treatment
was well tolerated.
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INTRODUCTION
Gastro-oesophageal reflux disease (GERD) is highly
prevalent, affecting up to 20% of the adult population
in North America.1 Up to 70% of GERD patients have
non-erosive reflux disease (NERD),2–5 a term used to
describe symptoms suggestive of GERD in patients
with no endoscopic evidence of erosive oesophagitis
(EO). The NERD population is heterogenous. Some
patients experience symptoms due to abnormal
oesophageal acid exposure, while others are symptom-
atic due to hypersensitivity to acid associated with
normal oesophageal acid exposure.6, 7 NERD patients
also have been found to have a more homoge-
neous intraoesophageal distribution of acid reflux and
are more likely to perceive acid reflux symptoms com-
pared with patients with EO.8, 9 Some patients with
GERD symptoms have no evidence of acid reflux. It
has been suggested that such patients may have
symptoms as a consequence of non-acid reflux,
inflammation, motility abnormalities or visceral hyper-
sensitivity.
Treatment of NERD can be a challenge for clinicians.
According to a recent systematic review, the pooled
rate for symptomatic response in NERD patients was
lower than for EO patients (37% vs. 56% respectively;
P < 0.0001) after 4 weeks of proton pump inhibitor
(PPI) therapy, using complete symptom resolution
(defined as no heartburn during the preceding 7 days)
as the outcome measure for comparison.10
Lansoprazole and its enantiomers are equipotent
inhibitors of proton pumps. The R-enantiomer, dexlan-
soprazole, constitutes >80% of circulating drug after
oral administration of lansoprazole and has a lower
clearance and fivefold greater systemic exposure than
the S-enantiomer.11 These pharmacokinetic advanta-
ges, much like the development of esomeprazole from
omeprazole12, 13 were important considerations for the
development of dexlansoprazole MR (TAK-390MR;
Takeda Global Research & Development Center, Inc.,
Deerfield, IL, USA), a novel modified-release formula-
tion of dexlansoprazole that employs a Dual Delayed
Release technology designed to prolong the dexlan-
soprazole concentration–time profile and provide
extended duration of acid suppression.14 This technol-
ogy uses two types of granules with different pH-
dependent dissolution profiles designed to release drug
in the proximal small intestine initially and, several
hours later, in the distal small intestine. The two sepa-
rate timings of drug-release produce a distinctive
two-peaked pharmacokinetic profile that extends the
duration of drug exposure by prolonging mean resi-
dence time (the average time a drug molecule spends
in the systemic circulation). To maintain pharmacolog-
ically active plasma dexlansoprazole concentrations, a
higher daily dose of dexlansoprazole MR is required
compared with conventional single-release drug deliv-
ery systems commonly used in PPI formulations.15
Preliminary data from phase 1 trials in healthy sub-
jects have shown that dexlansoprazole MR 30–90 mg
provides an increased pharmacodynamic effect and
that dexlansoprazole MR generally produced signifi-
cantly greater acid suppression than standard doses of
lansoprazole.15 An exposure–response analysis of data
from the phase 1 trials has suggested that doses lower
than 30 mg would produce less therapeutic effect.15
Therefore, the present study was designed to evalu-
ate the efficacy and safety of dexlansoprazole MR 30
and 60 mg once daily (QD) for 4 weeks compared with
placebo for relief of heartburn in patients with NERD.
Placebo is a standard comparator that has been used
in previous trials of similar design.16–22
METHODS
Study design
This was a phase 3, randomized, double-blind, multi-
centre, placebo-controlled, parallel-group, three-arm
study of 4 weeks duration (ClinicalTrials.gov No.
NCT00321984). The study was conducted in patients
with NERD who displayed normal mucosa (no EO) at
the screening endoscopy. The primary objectives were
to assess efficacy and safety of dexlansoprazole MR 30
and 60 mg administered QD compared with placebo
for the relief of heartburn for 24 h as recorded in a
daily electronic diary. The secondary objective was to
assess relief of nighttime heartburn.
Patients were randomized after a screening period
(minimum 7 days, maximum 21 days), during which
patients must have met all inclusion criteria and none
of the exclusion criteria. Patients received drug begin-
ning on day 1 and returned for visits at weeks 2 and 4
(or final visit) to assess GERD symptoms, complete
quality of life (QOL) and symptom severity question-
naires, review concomitant medication use and assess
adverse events (AEs). Study drug was collected at week
4 and rescue medication was returned at weeks 2 and 4,
with new rescue medication again dispensed at week 2.
At week 4 (or final visit), all patients underwent a
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complete physical examination that included vital signs
and blood samples were taken for fasting laboratory
evaluations including serum gastrin. Female patients
were required to undergo a serum pregnancy test at
screening and at week 4 (or final visit).
The study was approved by independent Institu-
tional Review Boards at participating study centres
and conducted according to the ethical principles sta-
ted in the 1996 Declaration of Helsinki. Each patient
signed an informed consent form and completed
Health Insurance Portability Accountability Act autho-
rization forms before any study-related procedure was
performed.
Patients
Patients were men and women (aged ‡18 years) who
identified heartburn as their primary symptom, had a
history of heartburn episodes for 6 months or longer,
experienced heartburn on at least 4 of the 7 days pre-
ceding randomization (as recorded in electronic dia-
ries) and showed normal oesophageal mucosa at the
screening endoscopy. Patients were enrolled regardless
of Helicobacter pylori status (assessed at screening by
finger stick or serology for H. pylori antibody).
Patients were instructed that lifestyle or behaviour
should not be altered to treat their GERD symptoms.
Patients were excluded for the following: pregnancy
or lactation; Barrett’s oesophagus; active gastric or
duodenal ulcers within 4 weeks of the first dose of
study drug; coexisting diseases affecting the oesopha-
gus or EO shown by endoscopy; history of gastric,
duodenal or oesophageal surgery; oesophageal stric-
tures requiring dilatation; use of a PPI, histimine-2
receptor agonist, antacid [except study-supplied Gelu-
sil (aluminium ⁄ magnesium hydroxide, simethicone;
Pfizer Inc., New York, NY, USA)], anticholinergic,
sucralfate or prokinetic agent during screening and
throughout the study; known hypersensitivity to PPIs
or Gelusil; long-term use (>12 doses ⁄ month) of non-
steroidal anti-inflammatory drugs within 30 days
before screening and throughout the study [low-dose
aspirin (£325 mg ⁄ day) was allowed during the study];
clinically significant abnormal laboratory values or
uncontrolled systemic disease.
Treatment assignment ⁄masking
On day )1, patients were randomized using Interactive
Voice Response System (IVRS; ClinPhone, Inc.,
Northbrook, IL, USA) in a 1:1:1 ratio to receive dex-
lansoprazole MR 30 mg QD, dexlansoprazole MR
60 mg QD or placebo. During the 4-week treatment
period, patients self-administered the study drug QD
before breakfast from blinded study-drug blister cards.
Dexlansoprazole MR and placebo capsules were manu-
factured and supplied by Takeda Pharmaceutical Com-
pany Ltd. (Osaka, Japan) and were packaged and
labelled by Fisher Clinical Services Inc. (Allentown,
PA, USA). Open-label Gelusil was provided as rescue
medication (up to six tablets per day). The investiga-
tors, study coordinators and patients remained blinded
to the treatments throughout the study.
Efficacy endpoints
The primary efficacy endpoint was the percentage of
24-h heartburn-free days (days with neither daytime
nor nighttime heartburn) during treatment as assessed
by a daily electronic diary. The secondary efficacy
endpoint was the percentage of nights without heart-
burn. Additional efficacy endpoints included percent-
age of days without daytime heartburn; mean severity
of heartburn; percentage of patients with 24-h heart-
burn-free days, nights without heartburn, and days
without daytime heartburn during the first 3 days of
treatment; time to sustained resolution of heartburn
(defined as the first occurrence of 7 consecutive 24-h
heartburn-free days); percentage of days without res-
cue medication use; investigator-reported symptom
severity at week 4 and patient-reported QOL and
symptom severity.
Efficacy assessments
Patients were given an electronic diary (personal digi-
tal assistant; Palm Tungsten E2, Palm Inc., and Inven-
tec Appliances Co., Ltd, both of Shanghai, China) on
the first day of the screening period for recording the
presence and maximum severity of daytime and night-
time heartburn and use of rescue medication. During
both the screening and treatment periods, patients
documented in the diaries the presence and severity of
heartburn twice daily (each evening before bedtime
and each morning upon awakening). Patients rated the
severity of heartburn according to the following five-
point scale: 0 = none, 1 = mild (occasional heartburn
that did not influence the patient’s daily routine),
2 = moderate (heartburn that could not be ignored;
occasionally influenced the patient’s daily routine),
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3 = severe (heartburn was present for most of the day;
regularly influenced patient’s daily routine) and
4 = very severe (constant heartburn; markedly influ-
enced patient’s daily routine). Similar five-point scales,
although not validated, have been used previously in
GERD studies.23–26 Nighttime was defined as time the
patient spent asleep. Only patients who recorded heart-
burn for ‡4 days during the 7 days before day )1 in
their electronic diaries were enrolled in the study.
Investigators also assessed GERD symptoms during
the day )1 visit as well as weeks 2 and 4 or final vis-
its. The maximum severity of symptoms (heartburn,
acid regurgitation, dysphagia, belching and epigastric
pain) was evaluated as none, mild, moderate, severe or
very severe during the 7 days before the patient’s
study visit and throughout the treatment period.
Patient-reported outcomes were assessed using two
validated, self-administered questionnaires during the
day )1 visit as well as weeks 2 and 4 or final visits.
The Patient Assessment of Upper Gastrointestinal Dis-
orders Quality-of-Life Index (PAGI-QOL) assesses
health-related QOL in patients with GERD, dyspepsia
and gastroparesis (subscales: daily activities, clothing,
diet and food habits, relationship, and psychological
well-being and distress).27 The PAGI-Symptom Sever-
ity Index (PAGI-SYM) is a brief symptom severity
instrument (subscales: nausea ⁄ vomiting, fullness ⁄ early
satiety ⁄ bloating, upper and lower abdominal pain and
heartburn ⁄ regurgitation).
Safety assessments
Safety of the study drugs was determined by system-
atic assessment of AEs at weeks 2 and 4 as well as by
physical examinations, vital signs, clinical laboratory
tests, electrocardiogram (planned for a subset of 540
patients), fasting serum gastrin levels and prior and
concomitant medication usage.
All AEs, whether observed by the investigator, elicited
during study visits, or spontaneously reported by the
patient, were collected from the day patients signed
informed consent forms and until 30 days after the last
day study drug was administered. Investigators
evaluated the severity of events and determined whether
the event(s) might have been related to study drug ther-
apy. Any clinically significant change in a laboratory
parameter was reported by the investigators as an AE.
Routine laboratory evaluations (haematology, chemistry
and urinalysis), serum pregnancy tests and fasting
serum gastrin levels were conducted.
Statistical analysis
A sample size of 240 patients (allowing for 20% drop-
out from 300 patients) per treatment group was
planned to provide at least 95% power at the 0.00125
level of significance to detect a 30% difference
between a dexlansoprazole MR dose (60%) and pla-
cebo (30%) for the primary efficacy variable. The use
of 0.00125 in the power calculation was conservative
to ensure sufficient power while accounting for multi-
plicity. The SAS ⁄ STAT software (SAS Institute Inc., Cary,
NC, USA) for the UNIX operating system was used to
perform statistical analyses. The overall level of signif-
icance was 0.0025 for efficacy variables, for which
Hochberg’s procedure for multiple comparisons was
used to ensure that the overall 0.0025 level of signifi-
cance was maintained for the two pairwise compari-
sons with placebo and 0.05 for demographic and
safety variables.
All randomized patients who received ‡1 dose of
study medication and completed the appropriate diary
entry (heartburn, heartburn severity, rescue medication
use) on ‡1 day during treatment were included in the
efficacy analysis [intent-to-treat (ITT) population] for
that variable. All patient diary data from days 1
through 35 and no later than the day of the last dose
of study drug were used in the efficacy analyses. Days
with missing diary results for each variable were
excluded from the numerator and denominator.
The primary efficacy endpoint was calculated as the
percentage of 24-h heartburn-free days out of the total
number of days for which either a daytime or night-
time result was recorded in diary entries. Pairwise
comparisons between each dexlansoprazole MR dose
and placebo were made using a Wilcoxon rank-sum
test.
Subgroup analyses for the primary efficacy variable
were conducted using pairwise comparisons between
all treatment groups. The van Elteren test was applied
with subgroup as the stratification factor. For analysis
of the secondary efficacy endpoint, comparisons
between dexlansoprazole MR and placebo were made
using Wilcoxon rank-sum test.
For the additional endpoints, comparisons were
analysed using Wilcoxon rank-sum tests. Over the first
3 days of treatment, the percentages of patients with
24-h heartburn-free days, nights without heartburn
and days without heartburn were calculated and treat-
ment comparisons were performed using Fisher’s exact
test. The percentage of subjects who achieved
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sustained resolution of heartburn, defined as having at
least 7 consecutive days of 24-h heartburn-free days
by the end of treatment, was obtained from the Kap-
lan–Meier estimates and summarized by treatment
group. Comparisons of the survival functions of the
time to first sustained resolution of heartburn between
treatment groups were performed using log-rank tests.
Analysis of investigator-assessed GERD symptom
severity was performed using a Cochran–Mantel–
Haenszel test for ordered responses with baseline
severity as the stratum. Analyses of the change from
baseline to week 4 in the PAGI-QOL total score and
the PAGI-SYM heartburn ⁄ regurgitation subscale were
performed for the ITT population. Within each treat-
ment group, the significance of the mean change from
baseline to week 4 vs. no change was tested with a
one-sample paired t-test. Pairwise comparisons for the
mean change values between the treatment groups
were made using contrast statements within the frame-
work of a one-way analysis of covariance model with
treatment group as the factor and baseline score as the
covariate.
The safety population included all patients who
received ‡1 dose of study medication. Treatment-
emergent AEs were summarized and comparisons
between treatment groups were made using Fisher’s
exact test.
RESULTS
Demographic and clinical characteristics
Investigators at 154 US centres enrolled patients and
conducted the study from June to December 2006. Nine
hundred forty-seven patients were randomized and
included in the safety analysis (Figure 1); 929 were
included in the ITT efficacy population. Eighteen
patients were not included in the ITT population (three,
eight and seven patients in the dexlansoprazole MR
30 mg, 60 mg and placebo groups respectively)
because they did not complete the appropriate diary
entry on ‡1 day during treatment. Six patients were
found to have Barrett’s oesophagus and three to have
EO, and therefore were discontinued from participating
n = 1042
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Figure 1. Patient disposition. QD, once daily.
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in the study. A total of 74 patients prematurely
discontinued: 21 from the dexlansoprazole MR 30-mg
group, 26 from the dexlansoprazole MR 60-mg group
and 27 from the placebo group. No significant
differences in reasons for premature discontinuation
were noted between treatment groups.
No statistically significant differences were observed
among the three groups in any baseline demographic
characteristic (Table 1). There was a statistically signifi-
cant difference among treatment groups in the number
of days with baseline daytime ⁄ nighttime heartburn
(P < 0.05). A greater percentage of patients in the pla-
cebo and dexlansoprazole MR 30-mg groups had 6–
7 days with daytime ⁄ nighttime heartburn compared
with the dexlansoprazole MR 60-mg group (80% and
76% vs. 68% respectively), while a greater percentage of
patients in the dexlansoprazole MR 60-mg group had
4–5 days of daytime ⁄ nighttime heartburn compared
with the placebo and dexlansoprazole MR 30-mg
groups (30% vs. 17% and 21% respectively). At baseline,
the median mean severity of heartburn on a five-point
scale ranged from 1.57 to 1.60 for patients with daytime
heartburn and from 1.21 to 1.36 for patients with day-
time ⁄ nighttime heartburn. All groups reported a median
mean severity for nighttime heartburn of 1.14 on a five-
point scale. The three treatment groups were similar
with respect to mean number of days on study drug and
extent of compliance with diary completion.













Men 84 (26.5) 84 (26.7) 106 (33.7) 274 (28.9)
Women 233 (73.5) 231 (73.3) 209 (66.3) 673 (71.1)
Ethnicity, n (%)
Hispanic or Latino 62 (19.6) 67 (21.3) 53 (16.8) 182 (19.2)
Not Hispanic or Latino 255 (80.4) 248 (78.7) 262 (83.2) 765 (80.8)
Race, n (%)
American Indian or Alaskan
Native
3 (0.9) 0 2 (0.6) 5 (0.5)
Asian 5 (1.6) 4 (1.3) 7 (2.2) 16 (1.7)
Black 45 (14.2) 37 (11.7) 48 (15.2) 130 (13.7)
Native Hawaiian or other
Pacific Islander
3 (0.9) 1 (0.3) 0 4 (0.4)
White 255 (80.4) 267 (84.8) 251 (79.7) 773 (81.6)
Multiracial 4 (1.3) 3 (1.0) 6 (1.9) 13 (1.4)
Unknown 2 (0.6) 3 (1.0) 1 (0.3) 6 (0.6)
Age (years)
Mean (s.d.) 47.6 (14.4) 47.6 (13.6) 47.5 (13.8) 47.5 (13.9)
Weight (kg)
n 317 315 314 946
Mean (s.d.) 80.5 (20.2) 80.8 (20.0) 83.3 (20.5) 81.5 (20.3)
BMI (kg ⁄ m2)
n 317 314 313 944
Mean (s.d.) 29.1 (6.7) 29.0 (6.8) 29.6 (7.0) 29.2 (6.8)
Helicobacter pylori status, n (%)
Positive 89 (28.1) 95 (30.2) 90 (28.6) 274 (28.9)
Alcohol use, n (%)
Drinker 182 (57.4) 162 (51.4) 181 (57.5) 525 (55.4)
Smoking status, n (%)
Smoker 52 (16.4) 72 (22.9) 57 (18.1) 181 (19.1)
All baseline demographics P > 0.05.
BMI, body mass index; MR, modified release; QD, once daily.
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Relief of daytime ⁄nighttime heartburn
The median percentage of 24-h heartburn-free days
was significantly greater in both the dexlansoprazole
MR 30- and 60-mg treatment groups compared with
the placebo group (54.9% and 50.0% vs. 18.5% respec-
tively; P < 0.00001; Figure 2). There was no statisti-
cally significant difference in treatment response
between the two dexlansoprazole MR treatment
groups. Dexlansoprazole MR 30- and 60-mg QD
remained significantly greater than placebo in control-
ling heartburn over 24 h after adjusting for the vari-
ous subgroup factors (age, gender, BMI, alcohol,
tobacco, H. pylori status and baseline symptom sever-
ity). There were no differences in efficacy between
H. pylori-positive and H. pylori-negative patients after
4 weeks of treatment with dexlansoprazole MR 30 or
60 mg. The percentage of patients who had neither
daytime nor nighttime (24-h) heartburn is presented
by each study day in Figure 3.
Relief of nighttime heartburn
The median percentage of nights for which patients
did not report having heartburn was significantly
greater for the dexlansoprazole MR 30- and 60-mg
treatment groups compared with the placebo group
(80.8% and 76.9% vs. 51.7%, respectively;
P < 0.00001; Figure 4). There was no significant dif-
ference between the two dexlansoprazole MR treat-
ment groups.
Additional efficacy variables
The median percentage of days for which patients did
not report having daytime heartburn was significantly
greater in both dexlansoprazole MR treatment groups
compared with the placebo group (63.0% for both
doses of dexlansoprazole MR vs. 26.9% for placebo,
P < 0.00001). The mean severity of heartburn was sig-
nificantly reduced in both dexlansoprazole MR treat-
ment groups compared with the placebo group for
daytime ⁄ nighttime heartburn (0.66 and 0.69 vs. 1.04
respectively), nighttime heartburn (0.56 and 0.60 vs.
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Figure 3. Percentage of patients with 24-h heartburn-free
days by each study day. (Note: there was no comparison






































Figure 4. Median percentage of nights without heartburn.
*P < 0.00001.
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(P < 0.00001 for all; Figure 5). There were no signifi-
cant differences between the two dexlansoprazole MR
treatment groups.
Over the first 3 days of treatment, dexlansoprazole
MR 30 and 60 mg were both significantly greater than
placebo in terms of the percentage of patients who
experienced 24-h heartburn-free days (13.9% and
16.2% vs. 2.2% respectively; P < 0.00001), nights
without heartburn (38.0% and 39.8% vs. 17.3%;
P < 0.00001) and days without heartburn (18.5% and
19.8% vs. 8.7%, P < 0.01). There were no significant
differences between the two dexlansoprazole MR treat-
ment groups.
A significantly greater percentage of patients in
both the dexlansoprazole MR 30- and 60-mg treat-
ment groups achieved sustained resolution of heart-
burn by the end of treatment compared with the
placebo group (59% and 42% vs. 14% respectively;
P < 0.00001). Patients in both the dexlansoprazole MR
30- and 60-mg treatment groups had a significantly
greater percentage of days without rescue medication
use compared with placebo-treated patients (median,
63.0% for both dexlansoprazole MR groups vs. 37.3%
for placebo; P < 0.00001; Figure 6).
For the investigator-assessed GERD symptoms,
patients receiving dexlansoprazole MR had signifi-
cantly less severe heartburn and acid regurgitation
compared with those receiving placebo. A greater per-
centage of patients in the dexlansoprazole MR 30- and
60-mg treatment groups had ‡1 category improvement
in investigator-assessed heartburn severity at week 4
compared with the placebo group (76.9% and 80.4%
vs. 56.6% respectively; P < 0.00001). In addition, for
acid regurgitation at week 4, more patients showed
improvement from baseline in the dexlansoprazole MR
30- and 60-mg groups than in the placebo group
(67.4% and 62.6% vs. 58.4% respectively), but this dif-
ference did not reach statistical significance.
The PAGI-SYM total score, as well as the subscale
scores for fullness ⁄ early satiety and heartburn ⁄ regurgi-
tation, was significantly better for the dexlansoprazole
MR treatment groups compared with the placebo
group at all patient visits (P < 0.005). For the PAGI-
QOL, the total score and score for the diet and food
habits subscale were significantly greater for both dex-
lansoprazole MR treatment groups compared with the
placebo group at all visits (P < 0.001).
Safety
The incidence of treatment-emergent AEs (a majority
of which were mild-to-moderate in severity) was 35%
for the dexlansoprazole MR 30-mg group, 32% for
the dexlansoprazole MR 60-mg group and 32% for
the placebo group. Diarrhoea, headache, and nausea
and vomiting were the most frequently reported (‡5%
of patients in any treatment group) treatment-
emergent AEs. There were no statistically significant
differences across treatment groups in the percentages
of patients who experienced ‡1 treatment-emergent
AE.
Six patients receiving dexlansoprazole MR 30 mg









































Figure 6. Mean percentage of days without rescue medi-
cation use. *P < 0.00001.
Placebo
Dexlansoprazole MR 30 mg
Dexlansoprazole MR 60 mg
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Figure 5. Mean severity of heartburn during treatment.
*P < 0.00001.
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60 mg (2.5%) and 11 patients receiving placebo (3.5%)
experienced ‡1 AE that may have led to withdrawal
from the study; there was no statistically significant
difference between any treatment group in the per-
centage of patients whose primary reason for discon-
tinuation was an AE. Four patients experienced eight
serious AEs (SAEs) during treatment (one who received
placebo, two who received dexlansoprazole MR 30 mg
and one who received dexlansoprazole MR 60 mg).
The SAEs were coronary artery occlusion secondary to
diabetes, hypertension and hypercholesterolemia in the
placebo-treated patient; myocardial infarction (MI) in
two patients with arteriosclerosis who received dexlan-
soprazole MR 30 mg (as well as a postsurgical cerebro-
vascular accident in one patient and post-MI
cardiogenic shock and sepsis in the other) and lower
abdominal pain and haematochezia in the patient trea-
ted with dexlansoprazole MR 60 mg following polyp
removal. There was no pattern to these events and all
were assessed by the investigator as not related to
study drug.
Increases in serum gastrin values from baseline to
week 4 were significantly greater (P < 0.001) in both
dexlansoprazole MR treatment groups (103.6 pg ⁄ mL
and 97.0 pg ⁄ mL in the dexlansoprazole MR 30- and
60-mg groups respectively) compared with placebo
(0.9 pg ⁄ mL); no statistically significant difference was
observed between the two dexlansoprazole MR treat-
ment groups (P = 0.545). The increases in serum gas-
trin levels were similar to those expected in patients
receiving PPI therapy and not clinically concerning.
No other clinically significant differences were
observed between the dexlansoprazole MR and placebo
treatment groups in clinical laboratory or vital signs
results.
DISCUSSION
This trial demonstrated that treatment with dexlansop-
razole MR 30 and 60 mg QD was significantly better
than placebo in providing 24-h heartburn-free days in
patients with NERD. Dexlansoprazole MR 30 and
60 mg were superior to placebo for the secondary
endpoint evaluating the percentage of nights without
heartburn. Heartburn relief occurred as early as the
first 3 days of dosing with dexlansoprazole MR
and was maintained throughout treatment;
significantly more patients achieved sustained heart-
burn resolution by the end of treatment. Patients
receiving dexlansoprazole MR experienced significant
improvements in the incidence and severity of heart-
burn in both patient and investigator assessments and
they used less rescue medication. The decreases in
symptom severity in patients treated with dexlansop-
razole MR probably contributed to the improved scores
patients achieved on both symptom severity and QOL
questionnaires. There were no statistically significant
differences between dexlansoprazole MR 30 and
60 mg in any clinical efficacy variables.
The therapeutic gains of 36.4 and 31.5 percentage
points respectively for dexlansoprazole MR 30 and
60 mg for 24-h heartburn-free days are somewhat
higher than the therapeutic gain achieved with other
PPIs in earlier trials; however, it is difficult to compare
results across trials because study designs and end-
points vary widely. Dean et al.10 performed a system-
atic review of seven placebo-controlled trials
published between 1980 and 2002 to compare the effi-
cacy of PPIs with placebo.16–22 Using defined endpoint
criteria to enable comparisons of symptom relief in
NERD patients treated with PPIs vs. placebo, the
authors estimated therapeutic gains for PPI treatment
that were similar to those reported in the current study
[from 30% to 35% for patients who achieved sufficient
heartburn control (defined as <1 day of moderate
heartburn during the preceding 7 days of treatment)
and from 25% to 30% for patients who achieved com-
plete symptom resolution (defined as no heartburn
during the preceding 7 days of treatment)]. Placebo is
a standard comparator for pivotal trials of this
kind;16–22 however, future trials with active compara-
tors would be required to evaluate fully the efficacy of
dexlansoprazole MR relative to other PPIs.
The increase in response to dexlansoprazole MR
over time in this study suggests that 28 days may not
be sufficient to evaluate the full symptomatic response
of NERD patients to PPI therapy. This finding is con-
sistent with a meta-analysis performed by Dean
et al.,10 which noted that symptom improvement in
NERD patients continues to increase from weeks 1 to 2
assessments and again at the week 4 assessment. The
authors speculated that patients with NERD may take
longer to achieve complete symptom response and
suggested that the duration of future studies in NERD
patients should be extended beyond the usual 1-month
time frame to observe the possibility of continued
symptom improvement.10
Symptom response rates in the current trial of dex-
lansoprazole MR were lower than those achieved in
trials evaluating dexlansoprazole MR in patients with
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EO, in which the median percentage of 24-h heart-
burn-free days ranged from 80.7% to 84.2% for dex-
lansoprazole MR 60 and 90 mg (vs. 80.7% for
lansoprazole 30 mg) after 4–8 weeks of treatment.28 It
is typical that the rate of symptom relief would be
lower (approximately 20%) in patients with NERD
compared with those with EO.10 This may be attrib-
uted, in part, to the fact that pH testing is generally
not performed at screening in NERD studies; therefore,
the percentage of patient population with symptoms
that were not acid-related is uncertain (i.e. those
patients with functional heartburn). Additionally, the
proportion of those with borderline reflux disease who
may also demonstrate a reduced response to a PPI
remains unknown.20 Patients with non-acid-related
symptoms would probably experience lower response
rates. Not excluding these patients from the trial better
reflects the heterogeneity of the overall NERD popula-
tion and treatment results that may be observed in
clinical practice. The absence of a dose response to
dexlansoprazole MR for most outcomes suggests that
further increasing the level of gastric acid suppression
in the NERD population offers little incremental value,
which may relate to the heterogeneity of this popula-
tion. The placebo response rate of 52% observed in
this study for the secondary endpoint, percentage of
nights without heartburn, was somewhat higher than
results seen in previous studies of GERD patients. The
lower prevalence of nighttime heartburn compared
with daytime heartburn in patients enrolled in this
study may have contributed to the high placebo
response rate. Additionally, nighttime symptoms were
not a requirement during screening in the current trial.
Other data also suggest that the placebo response can
be relatively high in patients with GERD and varies
across endpoints.29–31 The pattern of increase in pla-
cebo response over time observed in the current trial
has also been observed in trials of patients with func-
tional bowel disorders.32 In this trial, the phenomenon
may be driven by patients with functional heartburn,
who may account for a significant proportion of the
study population.
Both dexlansoprazole MR 30 and 60 mg were well
tolerated by patients in the current trial. The majority
of AEs were mild or moderate and no dose-related
trends were observed for treatment-emergent AEs.
Additionally, increases in serum gastrin seen in
patients treated with dexlansoprazole MR were similar
to those seen in earlier trials with lansoprazole, which
has a well-established safety profile.33
There were some limitations to the current study.
Similar to all previous studies evaluating the efficacy
of medical therapy for NERD, this trial relied upon
self-reported symptom-based endpoints to assess the
efficacy of dexlansoprazole MR. Some have criticized
such endpoints because of their lack of objectivity and
potential for recall bias. At present, symptom-based
endpoints are the accepted standard for treatment tri-
als in patients with NERD. We attempted to limit recall
bias through the use of electronic diaries, which
allowed timely capture of symptom data.
Additionally, assessing pH and oesophageal manom-
etry prior to randomization would have better charac-
terized the study population. As these assessments are
not routinely performed in trials of this type or in
clinical practice, the findings of the current trial may
be more generalizable than they would have been had
these procedures been performed. Finally, the impact
of the availability of over-the-counter PPIs on the cur-
rent study population remains uncertain. Use of over-
the-counter PPIs is more common today than in earlier
trials of other PPIs. Patients who fail to obtain relief
from over-the-counter PPIs may be more likely to seek
participation in current trials, potentially biasing the
study sample with more difficult-to-treat patients.
In conclusion, NERD patients treated with dexlan-
soprazole MR 30 and 60 mg QD experienced a signifi-
cantly higher percentage of 24-h heartburn-free days
than those treated with placebo. Furthermore, dexlan-
soprazole MR provided faster, more prolonged symp-
tom relief, less frequent and severe symptoms as
reported by patients and investigators and improved
QOL. Both doses of dexlansoprazole MR were well tol-
erated in this study. Dexlansoprazole MR demonstrated
a favourable safety profile, similar to that seen in pre-
vious trials evaluating lansoprazole.
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